Browsing Tag
HFpEF
2 posts
Does CADENCE confirm a scalable pathway for treating complex pulmonary vascular disease beyond pulmonary arterial hypertension?
WINREVAIR’s Phase 2 data signals expansion beyond pulmonary arterial hypertension. Find out what this means for Merck & Co., Inc. and the market.
AHA 2025 spotlight: sotagliflozin data spark debate on benefits in HFpEF patients without diabetes
Find out how sotagliflozin’s debated HFpEF results at AHA 2025 could change heart-failure therapy beyond diabetes.